Drug Database
Back to search

Netherlands· NL-bda3331402a2

Ontilyv 25 mg, harde capsules

A opicapone product containing opicapon, registered in Netherlands by BIAL - Portela & C, S.A.. The same ATC class is registered in 14 of our 19 countries.

ATC N04BX04

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedOntilyv 25 mg, harde capsulesATCN04BX04REGISTER NO.NL-bda3331402a2PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about opicaponAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Opicapone is registered in 14 of 19 countries.

Countries holding a registration under ATC N04BX04 (opicapone), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 10 of them publish a price we can compare per daily dose
Search opicapone products by name

Opicapone · ATC N04BX04

14 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of opicapone costs, country by country.

Normalised to the WHO defined daily dose (50 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Opicapone · price per daily dose (50 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$6.01
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
OPICAPON
Manufacturer
BIAL - Portela & C, S.A.
Country
Netherlands (NL)
ATC code
N04BX04
ATC class
Opicapone
Defined daily dose
50 mg, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/21/1578

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

69 interactions on record for opicapone.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check opicapone against other medicinesHow interaction checks work

Opicapone · interactions on record

69 records

  • 2 severe
  • 67 moderate

Most severe, free to view

  • ProcarbazineL01XB01severe
  • Methylthioninium chlorideV03AB17severe
  • EpinephrineA01AD01moderate
  • MetoclopramideA03FA01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Opicapone in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All opicapone products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Ongentys
  • Liechtenstein · Ongentys
  • Norway · Ongentys

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b89c5ec3-0a7a-4aec-afa3-0d4e8cf0c057
GET /v1/drugs/b89c5ec3-0a7a-4aec-afa3-0d4e8cf0c057?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/ontilyv-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Opicapone",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp128323",
  "excipients": [
    "AMMONIA (E 527)",
    "BLAUWE INKT",
    "ERYTHROSINE (E 127)",
    "GELATINE (E 441)",
    "INDIGOKARMIJN ALUMINIUMLAK (E 132)",
    "INDIGOKARMIJN ALUMINIUMLAK (E 132)",
    "LACTOSE 1-WATER",
    "MAGNESIUMSTEARAAT (E 470b)",
    "MAÏSZETMEEL, GEPREGELATINEERD",
    "NATRIUMZETMEELGLYCOLAAT",
    "PROPYLEENGLYCOL (E 1520)",
    "SCHELLAK (E 904)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "OPICAPON"
  ],
  "leaflet_url": null,
  "authorised_at": "2022/02/21",
  "procedure_number": "EMEA/H/C/005782",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/21/1578",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about opicapone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console